2-Amino-1-Pyrroline Hydrochloride CAS 7544-75-4 Purity >99.5% (HPLC) Tipiracil Hydrochloride Intermediate Factory
Manufacturer Supply, High Quality and Competitive Price
Tipiracil Hydrochloride (CAS: 183204-72-0) Related Intermediates
6-(Chloromethyl)uracil CAS: 18592-13-7
6-(Hydroxymethyl)uracil CAS: 22126-44-9
2-Amino-1-Pyrroline Hydrochloride CAS 7544-75-4
| Chemical Name | 2-Amino-1-Pyrroline Hydrochloride |
| Synonyms | 3,4-Dihydro-2H-Pyrrol-5-Amine Hydrochloride; 2-Aminopyrrolidine HCl |
| CAS Number | 7544-75-4 |
| CAT Number | RF-PI1838 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C4H8N2·HCl |
| Molecular Weight | 120.58 |
| Melting Point | 171.0 to 175.0℃ |
| Sensitive | Hygroscopic |
| Brand | Ruifu Chemical |
|
Item |
Specifications |
Results |
|
Appearance |
White Powder |
White Powder |
|
Purity / Analysis Method |
>99.5% (HPLC) |
99.8% |
|
Largest Single Impurity |
<0.50% |
0.09% |
|
Water Content (K.F) |
<0.50% |
0.45% |
|
Proton NMR Spectrum |
Conforms to Structure |
Conforms |
|
Test Standard |
Enterprise Standard |
|
|
Usage |
Intermediate of Tipiracil Hydrochloride (CAS: 183204-72-0) |
|
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
2-Amino-1-Pyrroline Hydrochloride (CAS: 7544-75-4) is a heterocyclic organic compound, which can be used as a pharmaceutical intermediate. 2-Amino-1-Pyrroline Hydrochloride is an intermediate of Tipiracil Hydrochloride (CAS: 183204-72-0) in the treatment of Rectal Cancer. Tipiracil Hydrochloride is a potent and competitive inhibitor of thymidine phosphorylase (TPase) with an IC50 value of 35 nM for human placental TPase. It is selective for TPase over other pyrimidine-metabolizing enzymes (IC50s = >1 mM for UPase, OPRTase, TK, and DPDase). TPI inhibits the phosphorolysis and degradation of trifluorothymidine, a cytotoxic nucleoside, in human breast and colon carcinoma tumor samples. Oral administration of TPI (12.5-50 mg/kg) enhances the anti-tumor activity of trifluorothymidine in a mouse AZ-521 stomach cancer xenograft model. Formulations containing TPI have been used for the treatment of metastatic colorectal cancer.
